STRIDE: Strength of The Calf Muscles and Their Role In Declining Effectiveness of Movement With Aging

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Leicester

About this trial

The calf muscles (plantarflexors) are the most important muscles for walking, running and daily activities. Weakness of these muscles through aging and disease significantly impact a person's ability to walk and complete daily activities. By assessing calf strength, it is possible to identify people at risk of falls, and a condition called sarcopenia (which means loss of muscle mass, strength and function). Unfortunately, most of the studies that have examined this have used specialist equipment unavailable to hospital staff. Our study aims to use commercially available equipment to explore the relationship between plantarflexor muscle strength and physical performance in adults living with or without sarcopenia, including those at risk of it. The study will determine if stronger/weaker calf muscles associated with sarcopenia influence the ability to walk and do things more easily. We will complete strength tests of the calf, thigh and hand, assess walking using a special camera system, use an ultrasound scan to look at the Achilles tendon, use a scan to look at how stiff your calf muscles are, assess your body composition, complete a physical performance test and some questionnaires. Each participant will complete the measures during one clinic visit

Eligibility criteria

Qualifiers

Participant is able and willing to provide informed consent to participate in the study

Aged 18 years or over

Ambulatory status: able to walk independently with or without aids

Able to attend clinic

Disqualifiers

Participant is unwilling or unable to give informed consent.

Palliative/ end of life

Moderate to severe communication difficulties/ cognitive function

Immobile

Trial design

Treatments tested in this trial

  • No intervention (observational study)

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Leicester

Lead sponsor

University Hospitals, Leicester

Collaborator